Teva chairman Frost will leave by the end of the year

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Teva chairman Frost will leave by the end of the year

Teva chairman Dr. Phillip Frost announced he would step down from the position "approximately by the end of this year," he wrote in a letter to shareholders. Frost happens to be Teva's largest individual shareholder with a stake worth $725 million and was due to retire in about a year, according to Reuters. "With the progress we have made, and continue to make, at Teva, I have advised the board that I believe it will be appropriate for me to step down as chairman," Frost said. Story

Teva
Dr. Phillip Frost
will step down as chairman.


InVivo Therapeutics
Steven McAllister joined as CFO.


Valeant Pharmaceuticals
Ryan Weldon is leaving the company.

Biotech

InVivo Therapeutics ($NVIV) has appointed Steven McAllister as chief financial officer. Release

Regulus Therapeutics ($RGLS) appointed Dr. Paul Grint as its chief medical officer. Release

Celerion named Dr. Robert Lester as the company's chief cardiologist and global medical director of cardiac safety services. Release

Florida-based InformedDNA named Duffy Oelberg its senior vice president for business development. Release

True North Therapeutics announced that Dr. James Gilbert will take over as chief medical officer. Release

Retrogenix has appointed Matthew Britz as its North American business development director. Release

Stephen Tulipano has joined Aldeyra Therapeutics ($ALDX) as the company's chief financial officer. Release

Stephen Ritter has joined Emotient as senior vice president of product development. Release

Neurotrope ($NTRP) has appointed Charles Ramat and Paul Frieman as co-chairmen of its board of directors. Release

Sangamo Biosciences ($SGMO) has appointed H. Stewart Parker to its board of directors. Release

Thrasos Therapeutics has appointed Donald Notman as chief financial officer and senior vice president. Release

Novavax ($NVAX) has appointed John Marsh Jr. as director emeritus of its board. Release

Algae Biomass Organization has appointed Matthew Carr as executive director. Release

Regado Biosciences ($RGDO) has named Drew Fromkin to its board of directors. Release

Sorbent Therapeutics has appointed Jay Shepard and William Waddill to the company's board of directors. Release

Dan Baker has joined Remedy Informatics as the company's senior vice president of sales. Release

Oxford BioTherapeutics has appointed Dr. Keith Wilson as chief scientific officer. Release

CannaVest ($CANV) has hired Stuart Tomc to spearhead the company's consumer health education and product development. Release

Chris Collins has joined Piper Jaffray as principal in its biotechnology investment banking group. Release

Pharma

Valeant's ($VRX) executive vice president, Ryan Weldon, will be leaving the company. Release

> South San Francisco's Global Blood Therapeutics has named Dr. Ted Love as its new CEO. Release

> Cardax has scooped up George Bickerstaff, former CFO of Novartis Pharma AG ($NVS), Tamar Howson, former senior business development executive at Bristol-Myers Squibb ($BMY) and SmithKline Beecham, and Terence Kelly, former senior Boehringer Ingelheim anti-inflammatory R&D executive and current CEO of CoMentis, as independent members of its board of directors. Release

> Sweden's Cantargia has named Dr. Goran Forsberg as CEO. Release

> Aerie Pharmaceuticals ($AERI) announced that Craig Skenes is its new vice president of business development. Release

Horizon Pharma ($HZNP) has named Paul Hoelscher as its chief financial officer and executive vice president, finance. Hoelscher will take the place of Robert De Vaere, the company's current chief financial officer. Release

> Erytech Pharma appointed Dr. Martine George and Hilde Windels as independent members of its board of directors. Release

> Brandon Kocher has joined Viscadia as an associate consultant. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.